BusinessCognition Therapeutics Co-Founder and CSO Susan Catalano to Present at the Annual ASENT MeetingBy Nasdaq OMXMar 6, 2018, 7:04 PM UTC
BusinessCognition Therapeutics to Participate in Leerink Partners 7th Annual Global Healthcare ConferenceBy Nasdaq OMXFeb 12, 2018, 2:01 PM UTC
BusinessCognition Therapeutics Co-Founder and CSO Susan Catalano to Present at Sachs Neuroscience Innovation ForumBy Nasdaq OMXJan 4, 2018, 1:05 PM UTC
BusinessCognition Therapeutics’ Alzheimer’s Disease Candidate CT1812 Meets Phase 1b/2a Study Objectives: Well Tolerated with Positive Influence on Biomarkers of Synapse RecoveryBy Nasdaq OMXNov 4, 2017, 2:45 PM UTC
BusinessFunction of Cognition Therapeutics’ Neurological Drug Screening Platform Presented at American Chemical Society National MeetingBy Nasdaq OMXAug 23, 2017, 1:45 PM UTC
BusinessCognition Therapeutics CEO Kenneth I. Moch to Present at Canaccord Genuity Annual Growth ConferenceBy Nasdaq OMXJul 31, 2017, 12:30 PM UTC
BusinessCognition Therapeutics Reports Drug-Drug Interaction Results for CT1812, a Disease-Modifying Alzheimer’s Disease CandidateBy Nasdaq OMXJul 19, 2017, 8:35 AM UTC
